Bisphosphonates in Kidney Disease-Safety First
- PMID: 33900635
- DOI: 10.1002/jbmr.4283
Bisphosphonates in Kidney Disease-Safety First
Comment on
-
Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis.J Bone Miner Res. 2021 May;36(5):820-832. doi: 10.1002/jbmr.4235. Epub 2021 Feb 8. J Bone Miner Res. 2021. PMID: 33373491
References
-
- Bikbov B, Perico N, Remuzzi G; on behalf of the GBD Genitourinary Diseases Expert Group. Disparities in chronic kidney disease prevalence among males and females in 195 countries: analysis of the Global Burden of Disease 2016 study. Nephron. 2018;139(4):313-318.
-
- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.
-
- Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-3232.
-
- Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14(7):570-576.
-
- Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86(4):810-818.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical